CASI Pharmaceuticals, Inc. (NASDAQ:CASI) – Investment analysts at Zacks Investment Research issued their Q2 2017 earnings per share estimates for shares of CASI Pharmaceuticals in a research note issued to investors on Wednesday. Zacks Investment Research analyst G. Zeng anticipates that the biotechnology company will earn ($0.03) per share for the quarter. Zacks Investment Research also issued estimates for CASI Pharmaceuticals’ FY2017 earnings at ($0.13) EPS.

A number of other research firms have also commented on CASI. Maxim Group restated a “buy” rating and issued a $4.00 price target on shares of CASI Pharmaceuticals in a research report on Friday, March 31st. ValuEngine upgraded shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday.

TRADEMARK VIOLATION NOTICE: “Brokers Issue Forecasts for CASI Pharmaceuticals, Inc.’s Q2 2017 Earnings (CASI)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at

Shares of CASI Pharmaceuticals (NASDAQ CASI) opened at 1.09 on Monday. The firm’s market cap is $65.61 million. The firm has a 50 day moving average of $0.99 and a 200 day moving average of $1.21. CASI Pharmaceuticals has a 52 week low of $0.87 and a 52 week high of $1.76.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01.

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Wellington Shields Capital Management LLC boosted its position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 37.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 728,447 shares of the biotechnology company’s stock after buying an additional 200,000 shares during the period. Wellington Shields Capital Management LLC owned about 1.21% of CASI Pharmaceuticals worth $1,034,000 as of its most recent SEC filing. 3.90% of the stock is owned by hedge funds and other institutional investors.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.